Madrigal Imaging Energie

Listing Results Madrigal Imaging Energie

Frequently Asked Questions

• What is madmadrigal pharmaceuticals?

  Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.

• What are the results of Madrigal’s mgl-3196 clinical trial?

  In Madrigal’s Phase 2 clinical trial, MGL-3196 achieved statistically significant results in the primary endpoint, the relative reduction of liver fat on magnetic resonance imaging-estimated proton density fat fraction, or MRI-PDFF, at 12-weeks.

• When will Madrigal’s resmetirom results be announced?

  We now expect to announce topline 52-week results from the study in January 2022.” Madrigal is currently conducting two Phase 3 Clinical trials, MAESTRO-NASH and MAESTRO-NAFLD-1, to demonstrate the safety and efficacy of resmetirom for the treatment of NASH.

• What happened to Madrigal’s blinded study data?

  Paul Friedman, M. D., Chief Executive Officer of Madrigal, stated, “Although the blinded study data were delivered to the vendor conducting the statistical analyses on time, unexpected staffing issues at the vendor delayed their analyses of the initial MRI-PDFF and lipid data planned for release by year end.

• Is mgl-3196 safe for pre-cirrhotic NASH?

  The other critical clinical area is safety, which must be pristine for therapy of pre-cirrhotic NASH with all its associated disorders and concomitant disease. More than 180 human subjects in phase 1 and 150 patients in phase 2 have been treated with MGL-3196 for up to 9 months without a significant safety signal reported.

• Does madrigal have a follow-on THR-β agonist in its pipeline?

  I would note that Madrigal has a follow-on THR-β agonist in its pipeline which presumably has enhanced chemical properties, which may be an important additional asset.

• Who’s best in class for Nash drugs?

  Title: Madrigal’s and Viking’s NASH Drugs: Who’s best in class? Two companies, Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX), this year reported clinical data on the activity of thyroid hormone receptor β (THR-β) agonists in the treatment of NASH, most recently on September 18, 2018 by Viking (see press release).

• Are Thr-β agonists effective for pre-cirrhotic NASH?

  The class of THR-β agonists is important in spectrum of potential therapeutic classes for treatment of pre-cirrhotic NASH. The clinical data so far provides ample encouragement to progress into late development.